These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 6781004

  • 1. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.
    Garrick NA, Murphy DL.
    Psychopharmacology (Berl); 1980; 72(1):27-33. PubMed ID: 6781004
    [No Abstract] [Full Text] [Related]

  • 2. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
    O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF.
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492
    [Abstract] [Full Text] [Related]

  • 3. Distribution and inhibition characteristics of human brain monoamine oxidase.
    Owen F, Cross AJ, Lofthouse R, Glover V.
    Biochem Pharmacol; 1979 Apr 01; 28(7):1077-80. PubMed ID: 444264
    [No Abstract] [Full Text] [Related]

  • 4. The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.
    Philips SR, Boulton AA.
    J Neurochem; 1979 Jul 01; 33(1):159-67. PubMed ID: 572413
    [No Abstract] [Full Text] [Related]

  • 5. The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
    Fowler CJ, Oreland L, Callingham BA.
    J Pharm Pharmacol; 1981 Jun 01; 33(6):341-7. PubMed ID: 6115003
    [No Abstract] [Full Text] [Related]

  • 6. Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
    Waldmeier PC, Delini-Stula A, Maître L.
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Jun 01; 292(1):9-14. PubMed ID: 934359
    [Abstract] [Full Text] [Related]

  • 7. Molecular turnover numbers of different forms of mitochondrial monoamine oxidase in rat.
    Egashira T, Ekstedt B, Kinemuchi H, Wiberg A, Oreland L.
    Med Biol; 1976 Aug 01; 54(4):272-7. PubMed ID: 957813
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of monoamine oxidase by clorgyline and deprenyl in circumventricular structures of rat brain.
    Kinemuchi H, Wakui Y, Arai Y, Kamijo K.
    Biochem Pharmacol; 1980 Oct 15; 29(20):2871-4. PubMed ID: 6776962
    [No Abstract] [Full Text] [Related]

  • 9. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
    Schoepp DD, Azzaro AJ.
    J Neurochem; 1981 Jun 15; 36(6):2025-31. PubMed ID: 6787175
    [Abstract] [Full Text] [Related]

  • 10. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA, Zagorevskiĭ VA, Lopatina KI, Sokolova TV, Gankina EM.
    Biull Eksp Biol Med; 1986 Aug 15; 102(8):170-2. PubMed ID: 3742029
    [Abstract] [Full Text] [Related]

  • 11. [Effect of protein denaturing reactions on retardation of the activity of rat liver mitochondrial monoamine oxidase by clorgyline and deprenyl].
    Severina IS.
    Biokhimiia; 1983 Sep 15; 48(9):1513-21. PubMed ID: 6414536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characterization of rat pulmonary monoamine oxidase.
    Kung HC, Wilson AG.
    Life Sci; 1979 Jan 29; 24(5):425-31. PubMed ID: 431330
    [No Abstract] [Full Text] [Related]

  • 14. A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
    Fagervall I, Ross SB.
    J Neurochem; 1986 Aug 29; 47(2):569-76. PubMed ID: 3734795
    [Abstract] [Full Text] [Related]

  • 15. The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline.
    Youdim MB, Holman B.
    J Neural Transm; 1975 Aug 29; 37(1):11-24. PubMed ID: 1159411
    [Abstract] [Full Text] [Related]

  • 16. Phenylethanolamine is a specific substrate for type B monoamine oxidase.
    Edwards DJ.
    Life Sci; 1978 Sep 18; 23(11):1201-7. PubMed ID: 713694
    [No Abstract] [Full Text] [Related]

  • 17. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
    Green AR, Mitchell BD, Tordoff AF, Youdim MB.
    Br J Pharmacol; 1977 Jul 18; 60(3):343-9. PubMed ID: 890205
    [No Abstract] [Full Text] [Related]

  • 18. Cumulative effects of irreversible MAO inhibitors in vivo.
    Felner AE, Waldmeier PC.
    Biochem Pharmacol; 1979 Apr 01; 28(7):995-1002. PubMed ID: 444293
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands.
    Lalies MD, Hibell A, Hudson AL, Nutt DJ.
    Ann N Y Acad Sci; 1999 Jun 21; 881():114-7. PubMed ID: 10415906
    [No Abstract] [Full Text] [Related]

  • 20. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.
    Azzaro AJ, King J, Kotzuk J, Schoepp DD, Frost J, Schochet S.
    J Neurochem; 1985 Sep 21; 45(3):949-56. PubMed ID: 3928811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.